Blueprint Medicines Stock Forecast, Price & News

+2.79 (+3.32 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume650,889 shs
Average Volume493,129 shs
Market Capitalization$5.07 billion
P/E Ratio15.44
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Blueprint Medicines logo

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.95 out of 5 stars

Medical Sector

101st out of 2,099 stocks

Pharmaceutical Preparations Industry

41st out of 830 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

Is Blueprint Medicines a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 6 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Blueprint Medicines stock.
View analyst ratings for Blueprint Medicines
or view top-rated stocks.

What stocks does MarketBeat like better than Blueprint Medicines?

Wall Street analysts have given Blueprint Medicines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Blueprint Medicines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Blueprint Medicines

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its earnings results on Wednesday, April, 28th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.80) by $0.08. The biotechnology company earned $21.58 million during the quarter, compared to analysts' expectations of $24.71 million. Blueprint Medicines had a trailing twelve-month return on equity of 27.25% and a net margin of 40.18%.
View Blueprint Medicines' earnings history

How has Blueprint Medicines' stock price been impacted by COVID-19?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BPMC shares have increased by 65.8% and is now trading at $86.90.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BPMC?

14 analysts have issued 1 year price objectives for Blueprint Medicines' stock. Their forecasts range from $81.00 to $152.00. On average, they anticipate Blueprint Medicines' stock price to reach $113.00 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Blueprint Medicines
or view top-rated stocks among Wall Street analysts.

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers M.B.A., J.D., MBA, CEO, Pres & Director (Age 50, Pay $1.2M)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 49, Pay $45k)
  • Mr. Michael Landsittel, CFO & Treasurer (Age 49, Pay $585.5k)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 45, Pay $733.96k)
  • Dr. Fouad Namouni, Pres of R&D (Age 52, Pay $661.58k)
  • Ms. Tracey L. McCain, Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. (Age 53, Pay $716.83k)
  • Ms. Ariel Hurley, Principal Accounting Officer, VP of Fin. & Controller (Age 47)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 58)
  • Dr. Percy H. Carter M.B.A., Ph.D., Chief Scientific Officer (Age 51)
  • Ms. Kristin Hodous, Sr. Mang. of Investor Relations

What is Jeff Albers' approval rating as Blueprint Medicines' CEO?

5 employees have rated Blueprint Medicines CEO Jeff Albers on Jeff Albers has an approval rating of 100% among Blueprint Medicines' employees. This puts Jeff Albers in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.64%), Price T Rowe Associates Inc. MD (6.94%), JPMorgan Chase & Co. (2.64%), TimesSquare Capital Management LLC (2.45%), Alliancebernstein L.P. (2.40%) and William Blair Investment Management LLC (1.82%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, Mark Alan Goldberg and Nicholas Lydon.
View institutional ownership trends for Blueprint Medicines

Which institutional investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Deerfield Management Company L.P. Series C, Eaton Vance Management, Morgan Stanley, Lord Abbett & CO. LLC, Voloridge Investment Management LLC, Rock Springs Capital Management LP, and Renaissance Technologies LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Mark Alan Goldberg, and Nicholas Lydon.
View insider buying and selling activity for Blueprint Medicines
or view top insider-selling stocks.

Which institutional investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Price T Rowe Associates Inc. MD, Oak Ridge Investments LLC, TimesSquare Capital Management LLC, Bank of New York Mellon Corp, Alliancebernstein L.P., Geode Capital Management LLC, and Woodline Partners LP.
View insider buying and selling activity for Blueprint Medicines
or or view top insider-buying stocks.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $86.90.

How much money does Blueprint Medicines make?

Blueprint Medicines has a market capitalization of $5.07 billion and generates $793.73 million in revenue each year. The biotechnology company earns $313.88 million in net income (profit) each year or $5.59 on an earnings per share basis.

How many employees does Blueprint Medicines have?

Blueprint Medicines employs 451 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is

Where are Blueprint Medicines' headquarters?

Blueprint Medicines is headquartered at 45 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.